Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
5
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,179.30 | 54.10 | 0.67% |
| CAC 40 | 7,482.36 | 155.89 | 2.13% |
| DAX 40 | 21,961.97 | 668.44 | 3.14% |
| Dow JONES (US) | 39,606.57 | 419.59 | 1.07% |
| FTSE 100 | 8,403.18 | 74.58 | 0.90% |
| HKSE | 22,013.48 | 59.14 | -0.27% |
| NASDAQ | 16,708.05 | 407.63 | 2.50% |
| Nikkei 225 | 35,244.41 | 375.78 | 1.08% |
| NZX 50 Index | 12,042.84 | 86.37 | 0.72% |
| S&P 500 | 5,375.86 | 88.10 | 1.67% |
| S&P/ASX 200 | 7,972.30 | 51.80 | 0.65% |
| SSE Composite Index | 3,310.40 | 14.04 | 0.43% |